LWCFA
TARA icon

Loring Wolcott & Coolidge Fiduciary Advisors’s Protara Therapeutics TARA Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-158
Closed -$16K – 727
2018
Q1 		$16K Hold
158
– – ﹤0.01% 556
2017
Q4 		$12K Hold
158
– – ﹤0.01% 560
2017
Q3 		$13K Buy
+158
New +$9.04K ﹤0.01% 544

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's TARA Position: Q2 2018 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Protara Therapeutics (TARA) in Q2 2018, closing a stake of 158 shares — an estimated $16K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in TARA in Q3 2017 and held it in 3 quarters. The position peaked at $16K in Q1 2018. 25 funds tracked by Wall St. Rank hold TARA as of Q2 2018.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Protara Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 158 Protara Therapeutics shares in Q2 2018, an estimated $16K.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Protara Therapeutics in Q3 2017 and held it in 3 quarters.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Protara Therapeutics position peaked at $16K in Q1 2018.
  • 25 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2018.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2018, filed 7 Aug 2018.